JP2013507930A5 - - Google Patents

Download PDF

Info

Publication number
JP2013507930A5
JP2013507930A5 JP2012534396A JP2012534396A JP2013507930A5 JP 2013507930 A5 JP2013507930 A5 JP 2013507930A5 JP 2012534396 A JP2012534396 A JP 2012534396A JP 2012534396 A JP2012534396 A JP 2012534396A JP 2013507930 A5 JP2013507930 A5 JP 2013507930A5
Authority
JP
Japan
Prior art keywords
polypeptide
chimeric
sequence
seq
hfgf19
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Granted
Application number
JP2012534396A
Other languages
English (en)
Japanese (ja)
Other versions
JP6016636B2 (ja
JP2013507930A (ja
Filing date
Publication date
Application filed filed Critical
Priority claimed from PCT/US2010/052852 external-priority patent/WO2011047267A1/en
Publication of JP2013507930A publication Critical patent/JP2013507930A/ja
Publication of JP2013507930A5 publication Critical patent/JP2013507930A5/ja
Application granted granted Critical
Publication of JP6016636B2 publication Critical patent/JP6016636B2/ja
Expired - Fee Related legal-status Critical Current
Anticipated expiration legal-status Critical

Links

JP2012534396A 2009-10-15 2010-10-15 改変したレセプター特異性を持つキメラ線維芽細胞増殖因子 Expired - Fee Related JP6016636B2 (ja)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
US25207409P 2009-10-15 2009-10-15
US61/252,074 2009-10-15
PCT/US2010/052852 WO2011047267A1 (en) 2009-10-15 2010-10-15 Chimeric fibroblast growth factors with altered receptor specificity

Publications (3)

Publication Number Publication Date
JP2013507930A JP2013507930A (ja) 2013-03-07
JP2013507930A5 true JP2013507930A5 (OSRAM) 2015-07-02
JP6016636B2 JP6016636B2 (ja) 2016-10-26

Family

ID=43876581

Family Applications (1)

Application Number Title Priority Date Filing Date
JP2012534396A Expired - Fee Related JP6016636B2 (ja) 2009-10-15 2010-10-15 改変したレセプター特異性を持つキメラ線維芽細胞増殖因子

Country Status (10)

Country Link
US (3) US8535912B2 (OSRAM)
EP (1) EP2488643A4 (OSRAM)
JP (1) JP6016636B2 (OSRAM)
KR (1) KR101952453B1 (OSRAM)
CN (1) CN102656266B (OSRAM)
BR (1) BR112012008907A2 (OSRAM)
CA (1) CA2777717C (OSRAM)
MX (2) MX2012004303A (OSRAM)
RU (1) RU2573896C2 (OSRAM)
WO (1) WO2011047267A1 (OSRAM)

Families Citing this family (47)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
JOP20190083A1 (ar) 2008-06-04 2017-06-16 Amgen Inc بولي ببتيدات اندماجية طافرة لـfgf21 واستخداماتها
WO2010129600A2 (en) 2009-05-05 2010-11-11 Amgen Inc. Fgf21 mutants and uses thereof
WO2010148142A1 (en) 2009-06-17 2010-12-23 Amgen Inc. Chimeric fgf19 polypeptides and uses thereof
US8889621B2 (en) 2009-10-30 2014-11-18 New York University Inhibiting binding of FGF23 to the binary FGFR-Klotho complex for the treatment of hypophosphatemia
EP2558115B1 (en) 2010-04-16 2019-07-31 The Salk Institute for Biological Studies Methods for treating metabolic disorders using fgf
PE20140260A1 (es) * 2010-11-05 2014-03-19 Pfizer Compuestos antidiabeticos
EP2726511B1 (en) * 2011-07-01 2019-08-07 NGM Biopharmaceuticals, Inc. Compositions, uses and methods for treatment of metabolic disorders and diseases
MX2014008699A (es) * 2012-01-18 2014-11-21 Genentech Inc Metodos para utilizar moduladores de fgf19.
US9475856B2 (en) 2012-03-02 2016-10-25 New York University Chimeric FGF21 proteins with enhanced binding affinity for β-klotho for the treatment of type II diabetes, obesity, and related metabolic disorders
US9474785B2 (en) 2012-06-07 2016-10-25 New York University Chimeric fibroblast growth factor 19 proteins and methods of use
US9657075B2 (en) * 2012-06-07 2017-05-23 New York University Chimeric fibroblast growth factor 23 proteins and methods of use
US9464126B2 (en) 2012-06-07 2016-10-11 New York University Chimeric fibroblast growth factor 21 proteins and methods of use
US9290557B2 (en) 2012-11-28 2016-03-22 Ngm Biopharmaceuticals, Inc. Compositions comprising variants and fusions of FGF19 polypeptides
EP2925775B1 (en) * 2012-11-28 2020-09-16 NGM Biopharmaceuticals, Inc. Compositions and methods for treatment of metabolic disorders and diseases
KR102724421B1 (ko) * 2012-12-27 2024-10-30 엔지엠 바이오파마슈티컬스, 아이엔씨. 담즙산 항상성의 조절 및 담즙산 질환 및 질병의 치료 방법
US9273107B2 (en) 2012-12-27 2016-03-01 Ngm Biopharmaceuticals, Inc. Uses and methods for modulating bile acid homeostasis and treatment of bile acid disorders and diseases
US9550820B2 (en) 2013-02-22 2017-01-24 New York University Chimeric fibroblast growth factor 23/fibroblast growth factor 19 proteins and methods of use
GB201316592D0 (en) * 2013-09-18 2013-10-30 Levicept Ltd Fusion protein
CN105828833A (zh) 2013-10-21 2016-08-03 萨克生物研究学院 突变的成纤维细胞生长因子（fgf）1及使用方法
WO2015061331A1 (en) 2013-10-21 2015-04-30 Salk Institute For Biological Studies Chimeric fibroblast growth factor (fgf) 2/fgf1 peptides and methods of use
KR102178945B1 (ko) * 2013-10-28 2020-11-13 엔지엠 바이오파마슈티컬스, 아이엔씨. 암 모델 및 관련 방법
SI3097122T1 (sl) 2014-01-24 2020-07-31 Ngm Biopharmaceuticals, Inc. Protitelesa, ki se vežejo v domeni beta klotho 2, in metode za njihovo uporabo
CN103816533A (zh) * 2014-02-27 2014-05-28 中国药科大学 Fgf19通过抑制胆汁酸合成发挥抗炎作用的应用
US20170065678A1 (en) 2014-03-11 2017-03-09 Novartis Ag Methods of treating metabolic disorders associated with lipodystrophies and defects in insulin production or signaling
CN106456714A (zh) 2014-03-28 2017-02-22 纽约大学 Fgf23融合蛋白
US20170173114A1 (en) * 2014-05-07 2017-06-22 Joslin Diabetes Center, Inc. Methods and compositions for induction of ucp1 expression
WO2015183890A2 (en) * 2014-05-28 2015-12-03 Ngm Biopharmaceuticals, Inc. Methods and compositions for the treatment of metabolic disorders and diseases
CA2951153A1 (en) 2014-06-16 2015-12-23 Ngm Biopharmaceuticals, Inc. Methods and uses for modulating bile acid homeostasis and treatment of bile acid disorders and diseases
WO2016048995A2 (en) * 2014-09-23 2016-03-31 Salk Institute For Biological Studies Fgf19 truncations and mutants and uses thereof
CN107108711B (zh) 2014-10-23 2021-11-23 恩格姆生物制药公司 包含肽变异体的药物组合物及其使用方法
US10434144B2 (en) 2014-11-07 2019-10-08 Ngm Biopharmaceuticals, Inc. Methods for treatment of bile acid-related disorders and prediction of clinical sensitivity to treatment of bile acid-related disorders
EP3108893A1 (en) * 2015-06-25 2016-12-28 Universite Claude Bernard - Lyon 1 Novel therapeutic use of fgf19
JP6951318B2 (ja) * 2015-07-15 2021-10-20 プロージット ソウル バイオテクノロジー （ベイジン） カンパニー リミテッド 融合ポリペプチドおよび使用方法
US10800843B2 (en) 2015-07-29 2020-10-13 Ngm Biopharmaceuticals, Inc. Beta klotho-binding proteins
AU2016344134A1 (en) 2015-10-30 2018-05-31 Salk Institute For Biological Studies Treatment of steroid-induced hyperglycemia with fibroblast growth factor (FGF) 1 analogs
JP6728352B2 (ja) 2015-11-09 2020-07-22 エヌジーエム バイオファーマシューティカルス，インコーポレーテッド 胆汁酸に関係した障害の治療方法
KR20170080526A (ko) * 2015-12-31 2017-07-10 한미약품 주식회사 Fgf21 아날로그, fgf21 결합체, 및 이의 용도
CA3034399A1 (en) 2016-08-26 2018-03-01 Ngm Biopharmaceuticals, Inc. Methods of treating fibroblast growth factor 19-mediated cancers and tumors
US20240076332A1 (en) * 2016-10-04 2024-03-07 Svar Life Science Ab FGF21 Responsive Reporter Gene Cell Line
CN107056925B (zh) * 2017-04-28 2022-01-14 中国科学院合肥物质科学研究院 人fgf21突变体、其制备方法及用途
SMT202400277T1 (it) 2017-12-22 2024-09-16 Novartis Ag Trattamento di disturbi metabolici con varianti di fgf21
RU2712770C1 (ru) * 2019-05-21 2020-01-31 Всеволод Викторович Мелехин Способ ингибирования роста опухолевых клеток
US11542309B2 (en) 2019-07-31 2023-01-03 Salk Institute For Biological Studies Fibroblast growth factor 1 (FGF1) mutant proteins that selectively activate FGFR1B to reduce blood glucose
WO2021092140A1 (en) * 2019-11-06 2021-05-14 Ngm Biopharmaceuticals, Inc. Methods of reducing lactate in liver disease patients using variants and fusions of fgf19/fgf21 polypeptides
CN114853869B (zh) * 2019-12-10 2023-12-26 湖南赛奥维生物技术有限公司 一种碱性成纤维细胞生长因子替代物及其组合物和应用
CN112972654B (zh) * 2021-03-05 2022-07-01 温州医科大学慈溪生物医药研究院 Fgf21在制备治疗脑神经损伤的药物中的应用
CN116284327A (zh) * 2023-03-28 2023-06-23 中国药科大学 一种靶向肿瘤的成纤维细胞生长因子19的重组蛋白及其应用

Family Cites Families (69)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US3773919A (en) * 1969-10-23 1973-11-20 Du Pont Polylactide-drug mixtures
US4179337A (en) * 1973-07-20 1979-12-18 Davis Frank F Non-immunogenic polypeptides
US4275149A (en) * 1978-11-24 1981-06-23 Syva Company Macromolecular environment control in specific receptor assays
US4657760A (en) * 1979-03-20 1987-04-14 Ortho Pharmaceutical Corporation Methods and compositions using monoclonal antibody to human T cells
JPS6023084B2 (ja) * 1979-07-11 1985-06-05 味の素株式会社 代用血液
US4399216A (en) * 1980-02-25 1983-08-16 The Trustees Of Columbia University Processes for inserting DNA into eucaryotic cells and for producing proteinaceous materials
ZA811368B (en) 1980-03-24 1982-04-28 Genentech Inc Bacterial polypedtide expression employing tryptophan promoter-operator
US4485045A (en) * 1981-07-06 1984-11-27 Research Corporation Synthetic phosphatidyl cholines useful in forming liposomes
NZ201705A (en) 1981-08-31 1986-03-14 Genentech Inc Recombinant dna method for production of hepatitis b surface antigen in yeast
US4640835A (en) * 1981-10-30 1987-02-03 Nippon Chemiphar Company, Ltd. Plasminogen activator derivatives
US4943529A (en) * 1982-05-19 1990-07-24 Gist-Brocades Nv Kluyveromyces as a host strain
US4713339A (en) 1983-01-19 1987-12-15 Genentech, Inc. Polycistronic expression vector construction
AU2353384A (en) 1983-01-19 1984-07-26 Genentech Inc. Amplification in eukaryotic host cells
US4816567A (en) * 1983-04-08 1989-03-28 Genentech, Inc. Recombinant immunoglobin preparations
US4544545A (en) * 1983-06-20 1985-10-01 Trustees University Of Massachusetts Liposomes containing modified cholesterol for organ targeting
AU3145184A (en) 1983-08-16 1985-02-21 Zymogenetics Inc. High expression of foreign genes in schizosaccharomyces pombe
US4496689A (en) * 1983-12-27 1985-01-29 Miles Laboratories, Inc. Covalently attached complex of alpha-1-proteinase inhibitor with a water soluble polymer
US4879231A (en) 1984-10-30 1989-11-07 Phillips Petroleum Company Transformation of yeasts of the genus pichia
EP0206448B1 (en) * 1985-06-19 1990-11-14 Ajinomoto Co., Inc. Hemoglobin combined with a poly(alkylene oxide)
US5206344A (en) * 1985-06-26 1993-04-27 Cetus Oncology Corporation Interleukin-2 muteins and polymer conjugation thereof
US4676980A (en) * 1985-09-23 1987-06-30 The United States Of America As Represented By The Secretary Of The Department Of Health And Human Services Target specific cross-linked heteroantibodies
JPS63502716A (ja) 1986-03-07 1988-10-13 マサチューセッツ・インステチュート・オブ・テクノロジー 糖タンパク安定性の強化方法
GB8610600D0 (en) 1986-04-30 1986-06-04 Novo Industri As Transformation of trichoderma
US4791192A (en) * 1986-06-26 1988-12-13 Takeda Chemical Industries, Ltd. Chemically modified protein with polyethyleneglycol
US4946783A (en) * 1987-01-30 1990-08-07 President And Fellows Of Harvard College Periplasmic protease mutants of Escherichia coli
US5010182A (en) * 1987-07-28 1991-04-23 Chiron Corporation DNA constructs containing a Kluyveromyces alpha factor leader sequence for directing secretion of heterologous polypeptides
ES2058199T3 (es) 1987-09-23 1994-11-01 Bristol Myers Squibb Co Heteroconjugados de anticuerpos para la eliminacion de celulas infectadas por el vih.
GB8724885D0 (en) 1987-10-23 1987-11-25 Binns M M Fowlpox virus promotors
ATE105585T1 (de) 1987-12-21 1994-05-15 Univ Toledo Transformation von keimenden pflanzensamen mit hilfe von agrobacterium.
AU4005289A (en) 1988-08-25 1990-03-01 Smithkline Beecham Corporation Recombinant saccharomyces
GB8823869D0 (en) * 1988-10-12 1988-11-16 Medical Res Council Production of antibodies
US5225538A (en) * 1989-02-23 1993-07-06 Genentech, Inc. Lymphocyte homing receptor/immunoglobulin fusion proteins
US5009772A (en) 1989-02-27 1991-04-23 Kerr-Mcgee Corporation Solvent extraction process
ES2055907T3 (es) 1989-03-07 1994-09-01 Genentech Inc Conjugados covalentes de lipidos y oligonucleotidos.
FR2646437B1 (fr) * 1989-04-28 1991-08-30 Transgene Sa Nouvelles sequences d'adn, leur application en tant que sequence codant pour un peptide signal pour la secretion de proteines matures par des levures recombinantes, cassettes d'expression, levures transformees et procede de preparation de proteines correspondant
ES2038579T3 (es) 1989-04-28 1997-02-16 Rhein Biotech Proz & Prod Gmbh Celulas de levadura del genero schwanniomyces.
WO1990013641A1 (en) 1989-05-10 1990-11-15 Sloan-Kettering Institute For Cancer Research Stably transformed eucaryotic cells comprising a foreign transcribable dna under the control of a pol iii promoter
EP0402226A1 (en) 1989-06-06 1990-12-12 Institut National De La Recherche Agronomique Transformation vectors for yeast yarrowia
DE3920358A1 (de) 1989-06-22 1991-01-17 Behringwerke Ag Bispezifische und oligospezifische, mono- und oligovalente antikoerperkonstrukte, ihre herstellung und verwendung
DE69029036T2 (de) 1989-06-29 1997-05-22 Medarex Inc Bispezifische reagenzien für die aids-therapie
FR2649120B1 (fr) 1989-06-30 1994-01-28 Cayla Nouvelle souche et ses mutants de champignons filamenteux, procede de production de proteines recombinantes a l'aide de ladite souche et souches et proteines obtenues selon ce procede
US5225212A (en) * 1989-10-20 1993-07-06 Liposome Technology, Inc. Microreservoir liposome composition and method
US5013556A (en) * 1989-10-20 1991-05-07 Liposome Technology, Inc. Liposomes with enhanced circulation time
CA2071483C (en) 1989-10-24 2001-04-17 Mark Matteucci Oligonucleotide analogs with novel linkages
US5545806A (en) * 1990-08-29 1996-08-13 Genpharm International, Inc. Ransgenic non-human animals for producing heterologous antibodies
US5661016A (en) * 1990-08-29 1997-08-26 Genpharm International Inc. Transgenic non-human animals capable of producing heterologous antibodies of various isotypes
JP2938569B2 (ja) * 1990-08-29 1999-08-23 ジェンファーム インターナショナル，インコーポレイティド 異種免疫グロブリンを作る方法及びトランスジェニックマウス
US5625126A (en) * 1990-08-29 1997-04-29 Genpharm International, Inc. Transgenic non-human animals for producing heterologous antibodies
US5633425A (en) * 1990-08-29 1997-05-27 Genpharm International, Inc. Transgenic non-human animals capable of producing heterologous antibodies
US5206161A (en) * 1991-02-01 1993-04-27 Genentech, Inc. Human plasma carboxypeptidase B
JPH06507398A (ja) 1991-05-14 1994-08-25 リプリジェン　コーポレーション Ｈｉｖ感染治療のための異種複合抗体
WO1993008829A1 (en) 1991-11-04 1993-05-13 The Regents Of The University Of California Compositions that mediate killing of hiv-infected cells
EP1136556B1 (en) 1991-11-25 2005-06-08 Enzon, Inc. Method of producing multivalent antigen-binding proteins
PT752248E (pt) 1992-11-13 2001-01-31 Idec Pharma Corp Aplicacao terapeutica de anticorpos quimericos e marcados radioactivamente contra antigenios de diferenciacao restrita de linfocitos b humanos para o tratamento do linfoma de celulas b
EP1013270A3 (en) * 1992-12-02 2001-03-28 Alkermes Controlled Therapeutics, Inc. Controlled release growth hormone containing microspheres
DE69519382T3 (de) 1994-09-09 2008-09-18 Takeda Pharmaceutical Co. Ltd. Zubereitung mit verzögerter freigabe eines metallsalz eines peptids
US5731168A (en) 1995-03-01 1998-03-24 Genentech, Inc. Method for making heteromultimeric polypeptides
RU2161502C2 (ru) 1995-06-07 2001-01-10 Элкермес Контролд Терапьютикс, Инк. Композиция для пролонгированного высвобождения гормона роста человека
ZA965368B (en) 1995-07-14 1997-01-14 Novo Nordisk As A pharmaceutical formulation
US20040126852A1 (en) * 1997-11-25 2004-07-01 Genentech, Inc. Fibroblast growth factor-19 (FGF-19) nucleic acids and polypeptides and methods of use for the treatment of obesity
AU733222B2 (en) * 1997-11-25 2001-05-10 Genentech Inc. Fibroblast growth factor-19
US7829693B2 (en) * 1999-11-24 2010-11-09 Alnylam Pharmaceuticals, Inc. Compositions and methods for inhibiting expression of a target gene
NZ543717A (en) * 2003-06-05 2008-06-30 Centelion Administration of a plasmid encoding a fibroblast growth factor (FGF), wherein VEGF-A factor expression is not induced in the myocardial or skeletal muscle to treat myocardial or skeletal angiogenic disorders or defects associated with hypercholesterolemia or diabetes
CA2565300A1 (en) * 2004-05-13 2005-12-01 Eli Lilly And Company Fgf-21 fusion proteins
TWI388568B (zh) * 2006-02-10 2013-03-11 Genentech Inc 抗ｆｇｆ１９抗體及其使用方法
WO2008153705A2 (en) * 2007-05-22 2008-12-18 Novartis Ag Methods of treating, diagnosing and detecting fgf21-associated disorders
TW200936156A (en) * 2008-01-28 2009-09-01 Novartis Ag Methods and compositions using Klotho-FGF fusion polypeptides
WO2010148142A1 (en) * 2009-06-17 2010-12-23 Amgen Inc. Chimeric fgf19 polypeptides and uses thereof
EP2726511B1 (en) * 2011-07-01 2019-08-07 NGM Biopharmaceuticals, Inc. Compositions, uses and methods for treatment of metabolic disorders and diseases

Similar Documents

Publication Publication Date Title
JP2013507930A5 (OSRAM)
JP7635291B2 (ja) 組織特異的Ｗｎｔシグナル増強分子およびその使用
RU2012119800A (ru) Химерные факторы роста фибробластов с измененной рецепторной специфичностью
CN101993496B (zh) 双重调节血糖血脂融合蛋白及其制法和用途
AU2014296107B2 (en) Growth differentiation factor 15 (GDF-15) constructs
KR102085605B1 (ko) 대사 장애를 치료하기 위한 융합 단백질
CA3223591A1 (en) Method of treating or ameliorating metabolic disorders using binding proteins for gastric inhibitory peptide receptor (gipr) in combination with glp-1 agonists
JP7734693B2 (ja) 抗ｃｄ２６タンパク質及びそれらの使用法
JP2017529059A5 (OSRAM)
KR20230029622A (ko) April 및 baff 억제 면역조절 단백질 및 사용 방법
TW201520224A (zh) 新穎胰島素類似物及其用途
CN108350054A (zh) 双功能蛋白质和包含其的药物组合物
JP2014508510A5 (OSRAM)
AU2015268199A1 (en) Composition for treating diabetes mellitus comprising insulin and a GLP-1/glucagon dual agonist
CN102770458A (zh) 用于增加Fc融合蛋白的血清半寿期的组合物和方法
HU230603B1 (hu) GLP1 fúziós fehérjék
JP2009513162A5 (OSRAM)
JP2008526233A (ja) Ｉｇｆ−ｉ融合ポリペプチドの組み合わせ治療用物質による肥満治療法
CN102766204A (zh) 胰高血糖素样肽-1突变体多肽及其制备方法和其应用
JP7191850B2 (ja) デュアル機能タンパク質およびその誘導体を生産するための方法
CN106279430B (zh) Exendin‑4类似物融合蛋白及其制备方法和用途
JP6320973B2 (ja) Ｂ細胞活性化因子の拮抗物質、その調製方法及び利用法
CA3238005A1 (en) Chimeric antigen receptors
US11026996B2 (en) Human Notch1 based fusion proteins as decoy inhibitors of jagged-notch signaling and DLL-notch signaling
RU2787060C1 (ru) НУКЛЕОТИДНАЯ ПОСЛЕДОВАТЕЛЬНОСТЬ, КОДИРУЮЩАЯ СЛИТЫЙ БЕЛОК, СОСТОЯЩИЙ ИЗ РАСТВОРИМОГО ВНЕКЛЕТОЧНОГО ФРАГМЕНТА ЧЕЛОВЕЧЕСКОГО Dll4 И КОНСТАНТНОЙ ЧАСТИ ТЯЖЕЛОЙ ЦЕПИ ЧЕЛОВЕЧЕСКОГО IgG4